ATTACHMENT U

2009 Cervical Cancer Screening Supplement

FORM NAMCS-CCS

U.S. DEPARTMENT OF COMMERCE O.S. DEPART MIERY OF COMMINERALE
Economics and Salatistics Administration
U.S. CENSUS BUREAU
ACTING AS DATA COLLECTION AGAIN FOR THE
U.S. Department of Health and Human Services
Contrors for Disease Control and Prevention
National Center for Health Statistics

NATIONAL AMBULATORY MEDICAL CARE SURVEY 2009 CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road, MS E-11, Atlanta, GA 30333, ATTN: PRA(0920-0234).

Assurance of Confidentiality - All information which would permit identification of an individual, a practice, or an establishment will be held confidential, will be used for statistical purposes only by NCHS staff, contractors, and agents only when required and with necessary controls, and will not be disclosed or released to other persons without the consent of the individual or establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m) and the Confidential Information Protection and Statistical Efficiency Act (PL-107-347).

BACKGROUND INFORMATION

0010	A. Provider's specialty (Mark (X) only ONE.) 1 ☐ General/Family 2 ☐ Internal 3 ☐ OB/ 4 ☐ CHC Mid-leve Practice Medicine GYN Provider	0015 B.	Census	contact r	name				
0020	C. Provider's serial number	0025 D.	Census contact telephor		Area code Number				
INTRODUCTION The Centers for Disease Control and Prevention is conducting a special survey on cervical cancer screening performed in community health centers and private office settings. Please answer the following questions. We appreciate your time on this important public health concern.									
1.	Does your practice use any of the following methods to scre	en for		Mark (X	() one inte	rval for n	outine sc		
a.	cervical cancer? Mark (X) all that apply. Conventional Pap test (Definition – Smear spread on glass si		Annually	Every 2 years	Every 3 years	More than 3 years	No routine interval recom- mended		
0055	See - How often does your practice routinely screen wousing this method? No Ontinue with item 1b	men	→	10	2	3	4	5	
	Liquid-based cytology (Definition – Specimen suspended in li 1	quid solutio	n)	1 10	2	3	4	5	
	Other – Specify д								
0065	1 Yes – How often does your practice routinely screen wo this method? 2 No 3 Unknown	men using	<u> </u>	 	2	3□	4	5	
2. 0050	Does your practice perform colposcopy? 1 Yes 2 No 3 Unknown								
151	CENSUSBUREAU								

	3a. Does your practice ever order or collect the Human Papillomavirus (HPV) DNA test? 1□ Yes – Go to item 3b 2□ No – SKIP to item 3c	If a patient's Pap test result is borderline or abnormal, does your practice routinely order an HPV DNA test to be performed on that sample (commonly called reflex HPV DNA testing)? (An HPV DNA test may be run on the same liquid-based medium as the Pap test						
	3 Not aware of HPV DNA test 4 Unknown 3 Not aware of HPV DNA test 3 Not aware of HPV DNA test 3 Not aware of HPV DNA test 3 on page 4	or an HPV DNA test specimen may be collected at the same time as the conventional Pap test.)						
	b. Which of the following HPV DNA tests are ordered or collected in your practice? Mark (X) all that apply.	0085 1 ☐ Yes – Go to item 4b						
00	0075 1 High risk (HR) HPV DNA test	3 Unknown SKIP to item 5a						
	2 ☐ Low risk (LR) HPV DNA test 3 ☐ Not aware there was a high risk or SKIP to	b. For which borderline or abnormal Pap test result would						
	low risk HPV DNA test 4□ Type-specific HPV DNA test	your practice order or collect a reflex HPV DNA test? Mark (X) all that apply.						
	s□ Unknown	ooeo 1 ASC-US (atypical squamous cells of undetermined significance)						
	Why is the HPV DNA test not ordered or collected in your practice? – Mark (X) all that apply.	2 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion)						
00	ooo	3☐ LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1)						
	2 My practice uses other tests, procedures, or examination methods to manage patients for whom the HPV DNA test is indicated.	4 HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ)						
	3 ☐ The patients in my practice have timely access to	5 ☐ AGC (atypical glandular cells)						
	colposcopy. 4 Assessing patients' HPV infection status is not a priority at my practice.	For which patients does your practice usually order reflex HPV DNA testing? – Mark (X) all that apply.						
	5 ☐ The labs affiliated with my practice do not offer the	0096 1 Women under 21 years old						
	HPV DNA test.	2 Women 21 years old to 29 years old 3 Women 30 years old and over						
	The health plans or health systems affiliated with my practice do not recommend the HPV DNA test.	4□ Other – Specify ⊋						
	7 The HPV DNA test is not a reimbursed or covered service for most patients in my practice.	5010						
	□ Discussing cervical cancer screening in the context of an STD is avoided in my practice.	5a. Does your practice routinely recall patients to come back for a second sample collection for an HPV DNA test if their Pap test is abnormal or borderline (recall testing)?						
	9 Notifying or counseling patients about positive HPV DNA test results would take too much time.	0100 1□ Yes – Go to item 5b						
	10 Notifying or counseling patients about positive HPV DNA test results might make clinicians in my practice feel uncomfortable.	2 No 3 Unknown SKIP to item 6a on page 3						
	. 11 Notifying or counseling patients about positive HPV DNA test results might make patients in my practice feel uncomfortable, angry, or upset.	b. For which abnormal or borderline Pap test result would your practice recall a patient for an HPV DNA test? Mark (X) all that apply.						
	processor to a disconnectable, dingry, or upoet	otos 1 ASC-US (atypical squamous cells of undetermined significance)						
	SKIP to item 7 on page 3.	2 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion)						
		3☐ LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1)						
		4 HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ)						
		5 ☐ AGC (atypical glandular cells)						
_ ^	200 0	EDDM NAMES COS (44 04 0000)						

Page 2 FORM NAMCS-CCS (11-21-2008)

	ia. Does your practice routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (commonly called adjunct HPV testing or cotesting)?										
0110	1 ☐ Yes – Go to item 6b										
	_	2 No 3 Unknown SKIP to item 7									
b.	For adju	For which patients does your practice routinely order or collect an HPV DNA test along with the Pap test (commonly called adjunct HPV testing or cotesting)? Mark (X) all that apply.									
0115		₁□ Women under 21 years old									
		2 Women 21 years old to 29 years old									
	_	3☐ Women 30 years old and over 4☐ Women who request the test for cervical cancer screening									
	50	₅☐ Women who request the test to check their HPV infection status									
	s ☐ Other – Specify ⊋										
5015											
7. Given the following screening histories, when would your practice recommend that a woman between 30 and 60 years of age return for her next Pap test?											
					For eac	ch of the fo	llowing scen	arios, mar	k (X) only	ONE for ea	ch row.
Prior Pap test results Current in past 5 years (excluding current pormal results)						Have no experience with this type of patient or test					
0120	(a)	Two consecutive normal Pap tests	Has not had test	Normal	10	2	3	4	5 🗆	e□	7□
0125	(b)	Two consecutive normal Pap tests	Negative	Normal	1	2	3	4 🗌	5 🗌	e 🗆	7
0130	(c)	Two consecutive normal Pap tests	Positive	Normal	1	2	3	4	5 🗌	6□	7
0135	(d)	Has not had a Pap test	Negative	Normal	10	2	3□	4	5 🗆	e□	7
0140	(e)	Has not had a Pap test	Positive	Normal	1	2	3	4 🗆	5 🗆	e□	7
0145	(f)	Abnormal Pap test	Negative	Normal	10	2	3	4 🗆	5 🗆	e□	7
0150	(g)	Abnormal Pap test	Positive	Normal	10	2	3□	4	5 🗆	6□	7
QUESTIONS 8-14 ASK ABOUT THE HPV VACCINE											
8.	Но	w often does your pr	ractice use	an HPV t	est to deter	mine who st	nould get the	HPV vaco	ine? Mark	(X) only one.	
	1 ☐ Rarely or never 2 ☐ Sometimes 3 ☐ Usually 4 ☐ Always or almost always 5 ☐ Do not recommend the HPV vaccine –SKIP to item 10.										

FORM NAMCS-CCS (11-21-2008) Page 3

9.	As it relates to the HPV vaccine, how often does your practice –									
	Mark (X) only ONE for each row.	Rarely or never	Sometimes	Usually	Always or almost always	applicable/ Do not ask				
0120	a. Use the number of sexual partners to determine who should get the HPV vaccine?	1	2	3 🗆	4	5				
0125	b. Perform a Pap test to determine who should get the HPV vaccine?	1 🗆	2	3□	4□	5 🗆				
0130	c. Recommend the HPV vaccine to females with a history of an abnormal Pap test result (ASC-US or higher)?	1	2	3 🗆	4	5				
0135	d. Recommend the HPV vaccine to females with a positive HPV test?	1 🗆	2	3□	4□	5				
10.	Will your practice's cervical cancer screenin management procedures change for female been fully vaccinated with the HPV vaccine?	s who have	1 Yes 2 No - SKIP to	SKIP to item 14						
11.	How will your practice determine when to st cervical cancer screening for fully HPV vacc females? Mark (X) all that apply.		vaccinate Specify 2 ☐ At a later	rage –						
			Specify 2 By onset of s How many ye onset of sexu 3 Will not be so 4 Unknown	exual activity – ear(s) since ual activity?———	→	ales				
12.	How often will your practice routinely screen cancer among females that have been fully with the HPV vaccine? Mark (X) one.	males that have been fully vaccinated 2 Every 2-3 years								
13.	Will your practice be using the HPV DNA test for managing abnormal cytology for females that have been fully vaccinated with the HPV vaccine? 1 □ Yes 2 □ No									
14.	Please indicate to what extent you agree, di with each statement. Please respond to both	Agree	Disagree	Unsure						
	There will be fewer numbers of abnorm among vaccinated females.	1□	2	3□						
	 There will be fewer referrals for colpose vaccinated females. 	1	2	3						
	The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is this practice currently participating in this state or national screening program? I Yes 2 No 3 Unknown									
	16. For purposes of this survey, which of the following categories describe your profession? – Mark (X) only ONE.									
	1 Physician 2 Physician assistant/ 3 Registered nurse 4 Other office staff Nurse practitioner/ Nurse midwife									

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.

Page 4 FORM NAMCS-CCS (11-21-2008)